心血管风险管理中的多种药物 - - 一个视角
Erlon Oliveira de Abreu-Silva1,2, Martin Siepmann3, Timo Siepmann2,4
1Hcor Research Institute, Hcor (IP-Hcor), Abílio Soares Street 250, São Paulo 04004-050, Brazil.
Journal of clinical medicine
|September 28, 2024
概括
多种药丸,即多种药物的组合在一个药丸中,可以简化治疗并改善患者对控制心血管疾病风险因素的坚持. 这一战略有可能在全球范围内改善心血管健康结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 心血管疾病及其风险因素构成了全球重大健康挑战.
- 对心血管风险因素的控制不足是常见的,尽管有大量关于治疗选择的证据.
- 患者不良坚持和有限的基于证据的治疗处方有助于低于最佳的心血管风险管理.
研究的目的:
- 审查当前关于在预防心血管疾病中使用多种药物的文献.
- 探索多药丸疗法在简化药物治疗和提高治疗坚持方面的潜力.
- 讨论与多种药物实施相关的未来挑战和机遇.
主要方法:
- 关于在心血管疾病中使用多药丸研究的文献综述.
- 影响治疗坚持和治疗处方的因素分析.
- 讨论多药片设计及其药理影响.
主要成果:
- 作为固定剂量组合的多药丸,旨在简化药物治疗方案.
- 多种药物的使用有可能显著改善患者对治疗的坚持.
- 目前正在审查关于多药在初级和二级心血管疾病预防中的有效性的证据.
结论:
- 多种药丸为简化药物治疗和改善心血管疾病管理的遵守提供了一个有希望的策略.
- 需要进一步的研究和实施战略,以应对未来的挑战,并最大限度地发挥多种药物的潜力.
- 优化多药丸的使用可以有助于更好地控制心血管风险因素的全球控制.
相关概念视频
Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
Peripheral Artery Disease III: Interprofessional Care
3
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
3
Coronary Artery Disease IV: Medical Management
11
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
11
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Hypertension IV: Drug Therapy and Lifestyle Modifications
3
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
3


